The U.K. Medicines and Healthcare Products Regulatory Agency has granted Promising Innovative Medicine designation to SGX945 (dusquetide) from Soligenix for the treatment of Behcet's Disease. This designation represents the first step toward potential inclusion in the U.K.'s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier than standard regulatory pathways would permit.
The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder. Behcet's Disease is a condition characterized by inflammation of blood vessels throughout the body, leading to symptoms that can include mouth sores, skin lesions, and eye inflammation, with potential serious complications affecting multiple organ systems.
For patients with rare diseases like Behcet's Disease, this regulatory designation is particularly significant because it creates a pathway to potentially access treatments that address unmet medical needs. The Early Access to Medicines Scheme is designed to balance the need for thorough safety evaluation with the urgency of providing potentially beneficial treatments to patients with serious conditions who have limited therapeutic options.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's development programs include expansion of synthetic hypericin (SGX302) into psoriasis, and dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, in addition to SGX945 in Behcet's Disease.
The company's Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses and CiVax, a vaccine candidate for the prevention of COVID-19. The development of these vaccine programs incorporates the use of proprietary heat stabilization platform technology known as ThermoVax. This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
This regulatory milestone represents progress in addressing the treatment gap for rare inflammatory diseases and demonstrates the potential for novel therapies to receive expedited regulatory consideration when they show promise for serious conditions with limited treatment options. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer, and the latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX.
